Our lab has studied the development of NK cells from stem cells and the acquisition of ki k:r immunoglobulin-like receptors (KIR) using in vitro models of differentiation. However, little is known about how and when NK cell receptor fate is determined in the setting of developing NK cells //; vivo. This question will be addressed by studies of NK cell reconstitution in patients undergoing unrelated marrow transplant with the goal of improving transplant outcome:;. Critical to the interpretation of these studies are controls for the genetic components that determine KIR expression. Allogeneic transplant is optimal for this study because each recipient is expected :o developdonor derived NK cells, that can be compared with their paired normal donor. The National Marrow Donor Progiam Sample Reposito/y will be invaluable tor the success of these studies. This resource, along with our novel system to quantitatively measure the expression of individual KIR gene products,will allow us to understand KIR expression and how it impacts on transplant outcomes. We have shown that KIR expression and NK cell function is markedly diminished after unrelated donor transplant in many recipients. The central hypothesis to be tested in this Project is that donor-de'ived NK cell function reconstituting after unrelated donor transplantation determines ^Jjnical iHiicpjnes. Function is determined by KIR acquisition mismatched for recipient MHC class I ligands on residual tumor cells cr APC to prevent and GVHD. Our current progress suggests that several signals influence KIR expression including 1L-3 and Il.-l'i, possibly through STATS pathways. We also address whether 1) KIR acquisition signals are mediated in an NK cell precursor, 2) IL-3 ? IL-15 induces a transcription factor in NK precursors which serves as a molecularswitch for KIR acquisition, 3) encountering class I MHC during development plays a role in the final KIR repertoire and 4) CD56*bngi"""""""" NK cells represent a distinct NK cell lineage after transplant, partially explaining the diminishedexpression of KIR aid other functional changes of biologic importance. The investigations are divided into the following three related specific aims:
In Specific Aim 1 NK cell receptor reconstitution after unrelated donor transplant will be studied and the influence of NK cell receptor repertoires on clinical outcomes will be determined. In Specific Ann 2 we will assess the developmentof NK cells and their precursors /'//vivo.
In Specific Aim 3 mechanisms of KIR acquisition in developirg NK cells will be studied.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA111412-03
Application #
7550551
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
3
Fiscal Year
2007
Total Cost
$241,647
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494

Showing the most recent 10 out of 108 publications